Lipid Profile and Nephropathy Progression in Diabetic Kidney Disease

Corresponding author: guliayimu·abulizi, gulayim@163.com

DOI: 10.12201/bmr.202609.00017

•  

  Abstract: Diabetic kidney disease (DKD) is the most common microvascular complication of diabetes, with progression closely linked to dyslipidemia. Traditional lipid markers have been consistently associated with DKD, yet their predictive performance is limited and do not fully account for residual risk. Emerging lipid biomarkers, including remnant cholesterol, lipoprotein(a) (Lp(a)), and the apolipoprotein B (ApoB)–containing lipoprotein family, have gained focused attention for their potential to more accurately gauge lipotoxic burden, glomerular inflammation, and fibrotic progression. These markers may enhance early warning and risk stratification, guiding timely intervention. This narrative review summarizes current evidence on lipid spectrum components in DKD development, with emphasis on the associations of remnant cholesterol, Lp(a), and ApoB with DKD, and discusses their roles in histopathologic changes, renal function decline, early screening, risk prediction, and dynamic assessment of therapeutic effects.

  Key words: Diabetic kidney disease；dyslipidemia； remnant cholesterol；lipoprotein(a)； apolipoprotein B

  Submit time: 9 September 2026

  Copyright: The copyright holder for this preprint is the author/funder, who has granted biomedRxiv a license to display the preprint in perpetuity.
• html

• 图表

• YAO Junxiao, WANG Lianzi, ZANG Yan, SHEN Mengjiao, LI Tao▲. Association Between Lipoprotein-to-Uric Acid Ratios and Nonalcoholic Fatty Liver Disease in Newly Diagnosed Type 2 Diabetes Patients. 2025. doi: 10.12201/bmr.202512.00017

  Liu Yanan, Zhan Ming, Han Fei. Research Progress and Prospects of Finerenone in the Treatment of Diabetic Nephropathy. 2024. doi: 10.12201/bmr.202410.00033

  Liu Shiwei. The predictive value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in the type 2 diabeticnephropathy. 2024. doi: 10.12201/bmr.202408.00066

  WANG Wenying, CAO Yanxia. Research Progress on the Mechanism and Clinical Efficacy of Finerenone in the Treatment of Diabetic Nephropathy. 2026. doi: 10.12201/bmr.202607.00028

  Jianbin Bi, Jiachao Lu, Baixu Chen, Hui Li, Jun Yan. Association Between the Serum Uric Acid to High-Density Lipoprotein Cholesterol Ratio and the Prevalence of Intracranial Aneurysms. 2026. doi: 10.12201/bmr.202604.00009

  shenzhouji, guofei. Research progress of histone modification and DNA methylation in diabetes nephropathy. 2024. doi: 10.12201/bmr.202407.00011

  Wang Anyu, Huang Jing, Zang Qianli, Zhao Sheng. Investigating the Mechanism of Danhuang Powder in Ameliorating Diabetic Nephropathy: Network Pharmacology Prediction and Molecular Docking Verification.. 2025. doi: 10.12201/bmr.202512.00029

  Zhang Mingchen. . 2026. doi: 10.12201/bmr.202603.00086

  ZHOU Jie, XIAO Wei. To explore the mechanism of oxidative stress and metabolic imbalance in COPD combined with type 2 diabetes from Qi-blood-body fluid theory. 2025. doi: 10.12201/bmr.202506.00039

  liruiyao, xujingyi, daihaoyu, sunhuiwen, wutianxing. Deep confidence network-based prediction of microvascular complications in type 2 diabetes mellitus. 2024. doi: 10.12201/bmr.202404.00021

• ID	Submit time	Number	Download
  1	2026-08-16	10.12201/bmr.202609.00017V1	Download

• Public  Anonymous  To author only Submit Comments